SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2017 / Cilt: 42 - Sayı: 1

Evaluation of prolidase activity in uremic bone disease

Üremik kemik hastalığında prolidase aktivitesinin değerlendirilmesi

Doğan YÜCEL
Murat DURANAY
Elmas ÖĞÜŞ
Arzu KÖSEM
Pages
23–29
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to our results, the prolidase activity decreased in CRF; and the level of decrement wasindependent from the hemodialysis procedure

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: In this study, we planned to evaluate the comparison of serum prolidase activity with other biochemical markers.Methods: The patient group was consisted of totally 73 patients with 21 male and 18 female who were diagnosed as chronic renal failure (CRF) and were undergoing peritoneal dialysis while 21 male and 13 female who were undergoing hemodialysis.
📊
Key Findings & Data:The control group was composed of 54 healthy volunteers, including 25 men and 29 women.
💡
Conclusion & Impact:According to our results, the prolidase activity decreased in CRF; and the level of decrement wasindependent from the hemodialysis procedure
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: In this study, we planned to evaluate the comparison of serum prolidase activity with other biochemical markers.Methods: The patient group was consisted of totally 73 patients with 21 male and 18 female who were diagnosed as chronic renal failure (CRF) and were undergoing peritoneal dialysis while 21 male and 13 female who were undergoing hemodialysis. The control group was composed of 54 healthy volunteers, including 25 men and 29 women. Serum and erythrocyte prolidase activities were measured in both patient and control groups and the relationship between serum prolidase activities and metabolic markers of bone (osteocalcin, bone-specific alkaline phosphatase, calcitonin, vitamin D and parathormone) were compared in both groups.Results: There was a significant difference between the serum prolidase activity of peritoneal dialysis and prehemodialysis groups as compared with the control group (p < 0.05). Serum prolidase activity of the pre-hemodialysis group was lower than that of post-hemodialysis group and there was a statistically significant difference (p < 0.05). There was a significant difference between prolidase activities in erythrocytes of prehemodialysis and control groups (p < 0.05)Conclusion: Kidney is the most prolidase-rich tissue in the human body. According to our results, the prolidase activity decreased in CRF; and the level of decrement wasindependent from the hemodialysis procedure

Özet

Amaç: Bu çalışmada, kronik böbrek yetmezliği (KBY) hastalarında diğer biyokimyasal belirteçler ile serum prolidaz aktivitesini değerlendirmek ve diyaliz işleminin prolidaz aktivitesi üzerine etkilerini incelemek amaçlanmıştır.Metod: Çalışmada hasta grubu KBY tanısı ile periton diyalizi uygulanan 21 erkek ve 18 kadın hasta ve hemodiyaliz uygulanan 21 erkek ve 13 kadın hasta olmak üzere toplam 73 hastadan oluşmaktaydı. Kontrol grubu ise 25 erkek ve 29 kadın olmak üzere toplam 54 sağlıklı gönüllüden oluşturuldu. Hasta gruplarında ve kontrol grubunda serum ve eritrosit prolidaz aktiviteleri ölçüldü ve prolidaz aktivitesi ile diğer kemik belirteçleri (osteokalsin, kemik spesifik alkalen fosfataz, kalsitonin, vitamin D, parathormon) arasındaki ilişki araştırıldı.Bulgular: Periton diyalizi ve hemodiyaliz giriş gruplarının serum prolidaz aktiviteleri kontrol grubu ile karşılaştırıldığında anlamlı bir fark bulundu (p < 0.05). Hemodiyaliz giriş grubunda serum prolidaz aktivitesi, hemodiyaliz çıkış grubuna göre düşüktü ve istatistiksel olarak anlamlı fark bulundu (p < 0.05). Hemodiyaliz giris ve kontrol grubu eritrosit prolidaz aktiviteleri arasında anlamlı fark vardı (p < 0.05).Sonuç: Böbrek, insan vücudunun prolidaz bakımından en zengin dokularından biridir. Sonuç olarak, prolidaz aktivitesi KBY'de düşmektedir ve bu düşüklük hemodiyaliz işleminden bağımsızdır

🔖

Cite This Article

YÜCEL, D., DURANAY, M., ÖĞÜŞ, E., KÖSEM, A. (2022). Evaluation of prolidase activity in uremic bone disease. Türk Biyokimya Dergisi, Cilt: 42 - Sayı: 1, 23–29. https://ajindex.com/articles/605971

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Urena P, Vrenejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999;55:2141–56
  2. Aljama P, Cruz JM, Martin de Francisco AL. New insights in ESRD. Kidney Int 2002;80:1–27
  3. Endo F, Tanoue A, Nakai H, Hata A, Indo Y, Titani K, et al. Primary structure and gene localization of human prolidase. J Biol Chem 1989;264:4476–81
  4. Myara I, Cosson C, Moatti N, Lemonnier A. Human kidney prolidase –purification, preincubation properties and immunological reactivity. Int J Biochem 1994;26:207–14
  5. Kobayashi M, Shimizu S. Cobalt proteins. Eur J Biochem 1999;261:1–9
  6. Tanaue A, Endo F, Matsuda I. Structural organization of the human prolidase and demonstration of a partial gene deletion in a patient with prolidase deficiency. J Biol Chem 1990;26:11306–11
  7. Myara I, Myara A, Mangeat M, Fabre M, Charpentier C, Lemonnier A. Plasma prolidase activity. A possible index of collagen catabolism in chronic liver disease. Clin Chem 1984;30:211–5
  8. Hui KS, Lajtha A. Prolidase activity in brain:comparison with other organs. J Neurochem 1978;30:321–7
  9. Mass DW, Henderson AR. Enzymes. In: Burtis CA, Ashwood ER, editors. Tietz tetxtbook of clinical chemistry. Philedelphia: Saunders, 1994:843
  10. Özcan Ö, Gültepe M, İpçioğlu OM, Bolat B, Kayadibi H. Optimisation of photometric enzyme activity measurement method in assessing absolute activity of prolidase. Turk J Biochem 2007;32:12–6
  11. Skorecki K, Green J, Brenner BM. Chronic renal failure. In: Braunwald E, Fauci AS, Kasper D, Longo DL, Hauser SL, Jameson JL, editors. Harrison principle of internal medicine. 16th ed. New York: McGraw Hill Company, 2005:1653–67
  12. Gejyo F, Kishore BK, Arakawa M. Prolidase and prolinase activities in the erythrocytes of patients with chronic uremia. Nephron 1983;35:58–61
  13. Ureña P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996;7:506–12
  14. Coen G, Ballanti P, Mazzaferro S, Pasquali M, Bonucci E. Procollagen type I C-terminal peptide, PTH and 1, 25 (OH)2 D3 in chronic renal failure. Bone 1993;14:415–20
  15. Evrenkaya TF, Atasoyu EM. The role of prolidase activity in the diagnosis of uremic bone disease. Renal Fail 2006;28:271–4
  16. Erbağcı AB, Araz M, Erbağcı A, Tarakçıoğlu M, Namıdur ES. Serum prolidase activity as a marker of osteoporosis in type 2 diabetes mellitus. Clin Biochem 2002;35:263–8
  17. Verit FF, Geyikli